Effect of exogenous p51a gene on the growth and chemo sensitivity of human lung adenocarcinoma cell lines

Abstract

Exogenous p51A gene can increase its expression in A549 and NCI-H1299 cells, suppress cell growth and induce cell apoptosis. Moreover, it can also cooperate with chemotherapy and reduce the dose and side-effect. p51A gene can suppress tumours in spite of p53 status and p21 gene might be involved. It might become a new promising therapeutic gene of tumours, which will make up for the limitation of p53 gene therapy.

5‐Hydroxymethylcytosine signature in circulating cell‐free DNA as a potential diagnostic factor for early‐stage colorectal cancer and precancerous adenoma

“…Most genes are associated with cancer pathogenesis. For instance, the top 1 gene in DhMRs between CRC patients and HCs was TP63, a new promising therapeutic member of the well-known TP53 family, which can suppress tumor cell growth, induce cell apoptosis, and cooperate with chemotherapy with low dose and less side effects [36]. The top hit between AD and HC groups, KLK4, kallikrein-related peptidase 4, has been implicated in many types of cancer and has potential as a tumor biomarker [37][38][39] which also predicts short-term relapse in colorectal adenocarcinoma patients [40].…”

Gene Therapy in Cancer Treatment: Why Go Nano?

“…Gene replacement can be accomplished by gene transduction, maintenance of stability and full expression of the gene, or by correcting gene mutations into its wild-type form (reviewed in [96]). Tumor suppressor genes, such as TP53, P21 or PTEN are major targets for gene replacement therapy [25,26,[97][98][99][100][101][102]. Due to the central role of P53 protein in cell cycle regulation, DNA repair, apoptosis, senescence and/or autophagy, TP53 gene is a major target for gene therapy [100].…”